Additional file 3: of SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Figure S3. Correlation between SNAI2 expression and PFS in patients with ER+ metastatic breast cancer from cohort 1 and 2 treated with fulvestrant. Kaplan-Meier plots evaluating PFS according to expression of SNAI2 in ER+ metastatic lesions from fulvestrant-treated patients from cohort 1 (A) and cohort 2 (B). A two-sided p value (*p < 0.05) was calculated using log-rank testing. (TIF 351 kb